Latest Filings

Issuer Activity

Insider Overview :: Medicure Inc. (V:MPH) [?]
Business Focus: Pharmaceuticals
Recent Price for MPH
CAD 0.240 0.00 (0.00%)
TSXV Delayed 15 minutes
May 16 0951 EDT
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
N/A 0.675 0.0 N/A 2.93
1-Day Low 52-Week Low Yield Avg. Volume  
N/A 0.200 0.0% 6,054  
Log in or sign up for a free account to add this stock to your watch list.
Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for MPH within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 17th, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
May 17/13 May 16/13 Kinley, James Direct Ownership Common Shares 10 - Acquisition in the public market 1,000 $0.240
May 15/13 May 10/13 Reimer, Dawson James Direct Ownership Options 50 - Grant of options 56,000 $0.300
May 14/13 May 10/13 Kinley, James Direct Ownership Options 50 - Grant of options 45,000 $0.300
May 14/13 May 10/13 Friesen, Albert David Direct Ownership Options 50 - Grant of options 75,000 $0.300
May 14/13 May 10/13 Merchant, Graeme William Direct Ownership Options 50 - Grant of options 45,000 $0.300
May 14/13 May 10/13 Naimark, Arnold Direct Ownership Options 50 - Grant of options 45,000 $0.300
May 14/13 May 10/13 McDole, Gerald P. Direct Ownership Options 50 - Grant of options 45,000 $0.300
May 14/13 May 10/13 Fawkes, Brent Jeffrey Direct Ownership Options 50 - Grant of options 45,000 $0.300
Apr 9/13 Apr 5/13 Friesen, Albert David Direct Ownership Common Shares 10 - Acquisition in the public market 30,000 $0.320
Apr 3/13 Apr 3/13 Friesen, Albert David Direct Ownership Common Shares 10 - Acquisition in the public market 10,000 $0.340
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for MPH within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 17th, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
May 17/13 May 16/13 Kinley, James Direct Ownership Common Shares 10 - Acquisition in the public market 1,000 $0.240
May 15/13 May 10/13 Reimer, Dawson James Direct Ownership Options 50 - Grant of options 56,000 $0.300
May 14/13 May 10/13 Kinley, James Direct Ownership Options 50 - Grant of options 45,000 $0.300
May 14/13 Sep 22/11 Kinley, James Direct Ownership Options 00 - Opening Balance-Initial SEDI Report    
May 14/13 May 10/13 Friesen, Albert David Direct Ownership Options 50 - Grant of options 75,000 $0.300
May 14/13 May 10/13 Merchant, Graeme William Direct Ownership Options 50 - Grant of options 45,000 $0.300
May 14/13 May 10/13 Naimark, Arnold Direct Ownership Options 50 - Grant of options 45,000 $0.300
May 14/13 May 10/13 McDole, Gerald P. Direct Ownership Options 50 - Grant of options 45,000 $0.300
May 14/13 May 10/13 Fawkes, Brent Jeffrey Direct Ownership Options 50 - Grant of options 45,000 $0.300
May 14/13 Jan 22/13 Fawkes, Brent Jeffrey Direct Ownership Options 00 - Opening Balance-Initial SEDI Report    
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for MPH on May 17, 2013 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Pharmaceuticals
Key People
Albert D. Friesen
Chairman of the Board, Chief Executive Officer 		Dawson J. Reimer
President, Chief Operating Officer 		James F. Kinley
Chief Financial Officer
Company Contact
Address: 2-1250 Waverley Street
WINNIPEG MB R3T 6C6
Tel: 1-888-4352220
Website: www.medicure.com
IR: www.medicure.com/stock.html
Business Overview
Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc.
Competitors with Recent Insider Filings
Paladin Labs (T:PLB)
Sophiris Bio (T:SHS)
Cipher Pharmaceuticals (T:DND)
 
Medicure Inc. Insider Report Only $20.00